Form 4 Filing for Katherine Stueland

Katherine Stueland, Chief Executive Officer and Director of GeneDx Holdings Corp., reported several transactions on March 15-16, 2026. Stueland acquired 11,921 shares of Class A Common Stock through the settlement of Restricted Stock Units (RSUs) with a reported value of $0.00 per share. Additionally, 18,750 shares were acquired under similar conditions. Subsequently, Stueland disposed of 7,178 shares for an average price of $76.35, 9,229 shares for an average price of $77.05, and 772 shares for an average price of $77.94. These sales were conducted to cover tax withholding obligations associated with the vesting and settlement of RSUs, as indicated by footnote 2. Following these transactions, Stueland beneficially owns 58,447 shares of Class A Common Stock, in addition to RSUs and stock options.